Abbisko Cayman Limited (HK:2256) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Abbisko Cayman Limited has announced the initiation of a Phase II clinical trial for its oral drugs ABSK061 and ABSK043, aimed at treating metastatic or unresectable solid tumors with FGFR2/3 alterations. These drugs have shown promising anti-tumor activity and a favorable safety profile in previous studies, making this trial a significant development for potential cancer treatments. Investors are advised to be cautious as the drugs are still under clinical evaluation.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia Stock Could Take a Beating from Supply Snags on Blackwell Chips
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
